GO:0004632 phosphopantothenate--cysteine ligase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004632 describes the molecular function phosphopantothenate--cysteine ligase activity, which catalyzes the ATP-independent, CTP-dependent formation of (R)-4'-phosphopantothenoyl-L-cysteine from (R)-4'-phosphopantothenate and L-cysteine.
• This reaction is the second step in the coenzyme A (CoA) biosynthesis pathway and is essential for producing CoA, a central cofactor in metabolism.
• The enzyme is encoded by PPCS in humans, and mutations in PPCS cause autosomal-recessive dilated cardiomyopathy.
• Bacterial and yeast orthologs, such as E. coli PPC synthetase and S. cerevisiae PPC synthetase, have provided detailed structural and mechanistic insights into the catalytic cycle.
• The enzyme is a validated target for antimicrobial drug discovery, with selective inhibitors developed against bacterial phosphopantothenoylcysteine synthetase.
• Research tools such as CRISPR knockout, point mutation, and overexpression models are critical for dissecting the role of PPCS in CoA metabolism and disease.
Description
Phosphopantothenate--cysteine ligase activity (GO:0004632) is a molecular function that catalyzes the second step in the biosynthesis of coenzyme A (CoA), a universally essential metabolic cofactor. The reaction joins (R)-4'-phosphopantothenate and L-cysteine to form (R)-4'-phosphopantothenoyl-L-cysteine, using CTP as the energy source and releasing CMP and diphosphate. This activity is conserved across bacteria, yeast, plants, and humans, and is encoded by the PPCS gene in humans. Because CoA is required for fatty acid oxidation, the tricarboxylic acid cycle, and numerous acetylation reactions, defects in this enzyme can have profound physiological consequences. Researchers study GO:0004632 to understand fundamental CoA homeostasis, to develop antibiotics targeting bacterial CoA biosynthesis, and to elucidate the molecular basis of rare inherited disorders such as dilated cardiomyopathy. Structural and mechanistic studies have revealed that the enzyme uses a unique CTP-dependent mechanism to activate the carboxylate of (R)-4'-phosphopantothenate, forming an acyl-cytidylate intermediate before cysteine attack. This mechanism distinguishes it from canonical ATP-dependent ligases and makes it an attractive target for selective inhibition. In this article, we provide a comprehensive overview of GO:0004632, covering its definition, catalytic mechanism, key genes, disease associations, and experimental models. We also highlight how CRISPR-based genome editing and functional genomics can accelerate research on this essential enzyme.
phosphopantothenate--cysteine ligase activity At A Glance
| GO ID | GO:0004632 |
|---|---|
| GO term | phosphopantothenate--cysteine ligase activity |
| Ontology | molecular_function |
| Synonym | phosphopantothenate-cysteine ligase activity; phosphopantothenoylcysteine synthetase activity; (R)-4'-phosphopantothenate:L-cysteine ligase activity |
| Major function | Catalyzes the second step of coenzyme A biosynthesis, forming (R)-4'-phosphopantothenoyl-L-cysteine from (R)-4'-phosphopantothenate and L-cysteine. |
| Cofactor | CTP is required as a nucleotide cofactor; the reaction is ATP-independent. |
| Subcellular location | Cytosol in eukaryotes; bacterial enzymes are cytosolic. |
| Pathway | Coenzyme A biosynthesis (KEGG pathway map00770). |
| Human gene | PPCS (phosphopantothenoylcysteine synthetase). |
What Is GO:0004632?
GO:0004632 phosphopantothenate--cysteine ligase activity is defined as the catalysis of the reaction: CTP + (R)-4'-phosphopantothenate + L-cysteine = CMP + diphosphate + (R)-4'-phosphopantothenoyl-L-cysteine. Cysteine can be replaced by some of its derivatives. In simpler terms, this enzyme activity links phosphopantothenate to cysteine in a reaction that consumes CTP and releases CMP and diphosphate, producing a key intermediate in coenzyme A biosynthesis.
Why Is phosphopantothenate--cysteine ligase activity Important in Cell Biology?
GO:0004632 is essential for coenzyme A biosynthesis, a pathway that provides the acetyl-group carrier central to energy metabolism, fatty acid synthesis and oxidation, and protein acetylation. In humans, loss-of-function mutations in PPCS cause autosomal-recessive dilated cardiomyopathy, highlighting the critical role of this enzyme in cardiac function. In pathogens such as Plasmodium falciparum and Entamoeba histolytica, the CoA biosynthesis pathway is a promising target for anti-infective drugs, and selective inhibitors of bacterial phosphopantothenoylcysteine synthetase have been developed. Understanding the molecular mechanism of this enzyme also informs the design of novel antibiotics and helps explain the metabolic basis of rare inherited diseases.
• Essential for coenzyme A biosynthesis, a central metabolic pathway.
• Mutations in human PPCS cause autosomal-recessive dilated cardiomyopathy.
• Validated drug target in bacterial pathogens; selective inhibitors exist.
• Plasmodium falciparum PPCS is a unique heteromeric complex and a target of pantothenate analogs.
• Entamoeba histolytica pantothenate kinase, upstream of PPCS, is a novel anti-amebic drug target.
• Mechanistic studies reveal a CTP-dependent peptide bond formation distinct from ATP-dependent ligases.
• Yeast and bacterial orthologs provide tractable models for structural and functional studies.
• Involved in metabolic reprogramming and potential cancer vulnerabilities.
• Supports research on CoA-related neurometabolic disorders and mitochondrial dysfunction.
• Enables development of species-selective inhibitors for antimicrobial therapy.
What Happens During phosphopantothenate--cysteine ligase activity?
Substrate Binding and CTP Activation
In simple terms: The enzyme grabs the two building blocks and uses CTP as an energy source to activate one of them.
The reaction begins with the binding of (R)-4'-phosphopantothenate and CTP to the enzyme active site. CTP is used to activate the carboxylate group of (R)-4'-phosphopantothenate, forming a mixed anhydride intermediate, (R)-4'-phosphopantothenoyl-cytidylate, with the release of diphosphate. This step is essential for subsequent peptide bond formation and distinguishes the enzyme from ATP-dependent ligases.
Cysteine Attack and Peptide Bond Formation
In simple terms: Cysteine then attacks the activated intermediate, linking the two molecules together.
Following activation, L-cysteine (or certain derivatives) attacks the carbonyl carbon of the acyl-cytidylate intermediate, displacing CMP and forming (R)-4'-phosphopantothenoyl-L-cysteine. This step completes the peptide bond formation and releases the product, which is the substrate for the next enzyme in the CoA pathway, phosphopantothenoylcysteine decarboxylase.
Product Release and Decarboxylation
In simple terms: The product is released and then further modified by another enzyme to continue CoA synthesis.
The product (R)-4'-phosphopantothenoyl-L-cysteine is released from the active site and serves as the substrate for phosphopantothenoylcysteine decarboxylase, which removes the carboxyl group to yield 4'-phosphopantetheine. This decarboxylation is a key step in coenzyme A biosynthesis and has been studied mechanistically.
Structural Basis of Catalysis
In simple terms: The enzyme's three-dimensional structure reveals how it positions the substrates for the reaction.
Crystallographic studies of the Saccharomyces cerevisiae and Escherichia coli enzymes have elucidated the catalytic mechanism, showing a conserved fold and key residues involved in CTP binding and catalysis. The bacterial dfp flavoprotein contains a phosphopantothenoylcysteine synthetase domain that shares mechanistic features with the stand-alone enzymes.
Key Genes Involved in GO:0004632 phosphopantothenate--cysteine ligase activity
The following genes and proteins are directly involved in or regulate phosphopantothenate--cysteine ligase activity (GO:0004632) and its associated pathways.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PPCS (human) | Encodes phosphopantothenoylcysteine synthetase, catalyzing GO:0004632 | Mutations cause dilated cardiomyopathy; target for metabolic studies |
| PPCS (S. cerevisiae) | Ortholog used in structural and mechanistic studies | Crystallographic analysis of catalytic mechanism |
| dfp (E. coli) | Bifunctional flavoprotein with PPC synthetase domain | Model for bacterial CoA biosynthesis and inhibitor design |
| coaB (B. subtilis) | Phosphopantothenoylcysteine synthetase | Target for antibacterial development |
| PPCS (P. falciparum) | Unique heteromeric complex with prokaryote-like activity | Target of pantothenate analogs for antimalarial drug discovery |
| PPCDC | Phosphopantothenoylcysteine decarboxylase, next enzyme in pathway | Mechanistic studies on CoA biosynthesis |
| PANK (E. histolytica) | Pantothenate kinase, upstream of PPCS | Novel anti-amebic drug target |
| COASY | Bifunctional enzyme in CoA biosynthesis | Related to CoA homeostasis and disease |
| SLC25A42 | Mitochondrial CoA transporter | Indirectly linked to CoA metabolism |
| ACACA | Acetyl-CoA carboxylase, uses CoA derivatives | Downstream metabolic readout |
| CPT1A | Carnitine palmitoyltransferase 1, requires CoA | Fatty acid oxidation link |
| PDHA1 | Pyruvate dehydrogenase, uses CoA | TCA cycle connection |
| HADHA | Trifunctional protein, fatty acid oxidation | CoA-dependent metabolic pathway |
| IDH2 | Isocitrate dehydrogenase, uses CoA | Mitochondrial metabolism |
| ACAT1 | Acetyl-CoA acetyltransferase | Ketone body metabolism |
| GCN5L1 | Regulates mitochondrial CoA levels | Potential upstream regulator |
How Is phosphopantothenate--cysteine ligase activity Regulated?
The expression and activity of phosphopantothenate--cysteine ligase are regulated at multiple levels. In bacteria, the dfp gene is part of the CoA biosynthesis operon and is subject to feedback regulation by CoA or its derivatives. In humans, PPCS expression may be influenced by metabolic demand and stress signals, although specific transcriptional regulators remain to be fully defined. The enzyme's activity can also be modulated by substrate availability, particularly cysteine and CTP levels, and by the redox state of the cell. Additionally, post-translational modifications and protein-protein interactions may affect its function, as suggested by the heteromeric complex observed in Plasmodium falciparum.
phosphopantothenate--cysteine ligase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PPCS | Autosomal-recessive dilated cardiomyopathy | Patient-derived iPSC-cardiomyocytes; PPCS knockout mouse |
| PPCS (P. falciparum) | Malaria; parasite CoA biosynthesis | P. falciparum culture; enzyme inhibition assays |
| coaB (B. subtilis) | Bacterial infections; CoA pathway | Bacterial growth inhibition; knockout strains |
| PANK (E. histolytica) | Amoebiasis; CoA biosynthesis | E. histolytica trophozoite culture; enzyme assays |
| PPCDC | CoA biosynthesis disorders | Yeast and mammalian cell models |
PPCS Mutations and Dilated Cardiomyopathy
Biallelic loss-of-function mutations in PPCS cause autosomal-recessive dilated cardiomyopathy, a severe heart muscle disorder characterized by ventricular dilation and impaired systolic function. These mutations reduce CoA levels and impair mitochondrial fatty acid oxidation, leading to energy deficiency in cardiomyocytes. This discovery established PPCS as a novel disease gene and highlighted the importance of CoA biosynthesis in cardiac health.
Infectious Disease Targets
The CoA biosynthesis pathway is essential in many pathogens, and phosphopantothenate--cysteine ligase is a promising drug target. Selective inhibitors of bacterial phosphopantothenoylcysteine synthetase have been developed, showing efficacy against Gram-positive bacteria. In Plasmodium falciparum, the PPCS enzyme forms a unique heteromeric complex with prokaryote-like activity and is targeted by pantothenate analogs, offering a new avenue for antimalarial therapy. Similarly, Entamoeba histolytica pantothenate kinase, upstream in the pathway, is a validated anti-amebic target.
Metabolic and Neurological Implications
CoA deficiency due to impaired PPCS activity can affect multiple organs, particularly those with high energy demands such as the heart and brain. While PPCS mutations primarily manifest as cardiomyopathy, secondary metabolic disturbances may contribute to neurological symptoms. Understanding these connections could lead to therapeutic strategies targeting CoA metabolism.
From phosphopantothenate--cysteine ligase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does PPCS loss impair CoA levels and cardiac function? | PPCS knockout mouse or human iPSC-derived cardiomyocytes |
| What is the catalytic mechanism of PPCS? | Recombinant yeast or bacterial enzyme; crystallography |
| Can selective inhibitors target bacterial PPCS? | Bacterial strains with coaB deletion; inhibitor screening |
| How does PPCS mutation affect metabolic flux? | CRISPR point-mutation knock-in cell lines; metabolomics |
| Does PPCS overexpression rescue CoA deficiency? | Lentiviral overexpression in patient fibroblasts |
| What is the role of PPCS in Plasmodium? | P. falciparum transgenic lines; pantothenate analog treatment |
How to Study the phosphopantothenate--cysteine ligase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Enzymatic coupled assay | CTP consumption or CMP production | Kinetic characterization and inhibitor screening |
| X-ray crystallography | Three-dimensional structure of enzyme-substrate complexes | Mechanistic studies and inhibitor design |
| LC-MS metabolomics | Intracellular CoA and intermediate levels | Functional validation of PPCS mutations |
| CRISPR knockout | Loss-of-function phenotypes | Gene essentiality and disease modeling |
| CRISPR point mutation | Effect of specific disease variants | Genotype-phenotype correlation |
| Overexpression | Gain-of-function and rescue experiments | CoA restoration studies |
| RNA-seq | Transcriptional changes upon PPCS perturbation | Pathway analysis and biomarker discovery |
| Proteomics | Protein expression and interaction networks | Identification of PPCS complexes |
Enzymatic Assays for Ligase Activity
Direct measurement of phosphopantothenate--cysteine ligase activity can be performed using coupled enzymatic assays that monitor CTP consumption or CMP formation. Radioactive or fluorescently labeled substrates allow sensitive detection of product formation. These assays are essential for kinetic characterization and inhibitor screening.
Structural Biology and Crystallography
X-ray crystallography of PPCS from Saccharomyces cerevisiae and Escherichia coli has revealed the atomic details of substrate binding and catalysis. These structures guide the design of species-specific inhibitors and help interpret disease-causing mutations.
Metabolomics and CoA Quantification
Liquid chromatography-mass spectrometry (LC-MS) can quantify CoA and its intermediates in cells and tissues, providing a functional readout of PPCS activity. Metabolomic profiling of patient samples or knockout models reveals downstream metabolic consequences.
CRISPR-Based Functional Genomics
CRISPR knockout, point mutation, and overexpression models enable precise interrogation of PPCS function in human cells. Pooled CRISPR screens can identify synthetic lethal interactions and pathways that compensate for PPCS loss.
How CRISPR Can Be Used to Study GO:0004632 phosphopantothenate--cysteine ligase activity
Knockout
CRISPR knockout of PPCS in human cell lines or animal models abolishes phosphopantothenate--cysteine ligase activity, leading to CoA depletion and impaired mitochondrial metabolism. These models are invaluable for studying the consequences of CoA deficiency and for testing rescue strategies.
Point Mutation
Introducing patient-specific PPCS mutations (e.g., missense variants) via CRISPR point mutation allows precise modeling of dilated cardiomyopathy and assessment of mutation severity. Such models help distinguish loss-of-function from hypomorphic alleles.
Knock-in
Knock-in of tagged PPCS (e.g., FLAG or GFP) enables localization, interaction, and stability studies in a physiological context. Tagged knock-in models are also useful for proteomic analysis of PPCS complexes.
Overexpression
CRISPR-mediated overexpression or lentiviral delivery of PPCS can rescue CoA levels in patient cells and test whether increased enzyme activity ameliorates disease phenotypes. Overexpression models also help identify downstream metabolic effects.
How EDITGENE Supports phosphopantothenate--cysteine ligase activity Research
Researchers studying phosphopantothenate--cysteine ligase activity-related genes often need to determine whether a candidate gene is causally involved in CoA metabolism, cardiac function, or microbial viability. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research, from gene knockout to precise point mutations and library screening.
Contact EDITGENE today to design your custom CRISPR model for phosphopantothenate--cysteine ligase activity research.
Frequently Asked Questions About phosphopantothenate--cysteine ligase activity
What is phosphopantothenate--cysteine ligase activity?
It is a molecular function (GO:0004632) that catalyzes the second step in coenzyme A biosynthesis, joining (R)-4'-phosphopantothenate and L-cysteine in a CTP-dependent reaction.
What genes are involved in phosphopantothenate--cysteine ligase activity?
The human gene is PPCS; bacterial orthologs include dfp and coaB, and yeast uses PPCS.
What is the role of PPCS in disease?
Mutations in PPCS cause autosomal-recessive dilated cardiomyopathy due to impaired CoA biosynthesis.
How is phosphopantothenate--cysteine ligase activity regulated?
It is regulated by substrate availability, feedback inhibition by CoA derivatives, and potentially by protein-protein interactions.
What is the reaction catalyzed by GO:0004632?
CTP + (R)-4'-phosphopantothenate + L-cysteine = CMP + diphosphate + (R)-4'-phosphopantothenoyl-L-cysteine.
Is phosphopantothenate--cysteine ligase a drug target?
Yes, it is a validated target for antibacterial and antimalarial drug discovery, with selective inhibitors developed.
What model systems are used to study GO:0004632?
Bacterial and yeast enzymes, human cell lines, iPSC-derived cardiomyocytes, and knockout mouse models.
How can CRISPR help study phosphopantothenate--cysteine ligase activity?
CRISPR knockout, point mutation, and overexpression models enable precise functional dissection of PPCS in health and disease.
What is the connection between PPCS and coenzyme A?
PPCS catalyzes a key step in CoA biosynthesis; loss of PPCS reduces CoA levels and impairs metabolism.
Are there inhibitors of phosphopantothenate--cysteine ligase?
Yes, selective inhibitors of bacterial phosphopantothenoylcysteine synthetase have been reported.
Conclusion
Phosphopantothenate--cysteine ligase activity (GO:0004632) is a fundamental enzymatic function in coenzyme A biosynthesis, with critical roles in metabolism, cardiac health, and microbial pathogenesis. Structural and mechanistic studies have illuminated its unique CTP-dependent catalytic mechanism, and genetic studies have linked PPCS mutations to dilated cardiomyopathy. The enzyme is also a promising target for anti-infective therapies. Continued research using CRISPR-based models and advanced omics will further unravel its regulation and therapeutic potential.
References
- 1. Nurkanto A et al.. 2018. Characterization and validation of Entamoeba histolytica pantothenate kinase as a novel anti-amebic drug target.. Int J Parasitol Drugs Drug Resist 8(1):125-136 PMID: 29518650
- 2. Liu X et al.. 2026. The Plasmodium falciparum PPCS is a unique heteromeric complex with prokaryote-like activity and is a target of pantothenate analogs.. Sci Adv 12(11):eadx5265 PMID: 41824577
- 3. Iuso A et al.. 2018. Mutations in PPCS, Encoding Phosphopantothenoylcysteine Synthetase, Cause Autosomal-Recessive Dilated Cardiomyopathy.. Am J Hum Genet 102(6):1018-1030 PMID: 29754768
- 4. Zheng P et al.. 2019. Crystallographic Analysis of the Catalytic Mechanism of Phosphopantothenoylcysteine Synthetase from Saccharomyces cerevisiae.. J Mol Biol 431(4):764-776 PMID: 30653991
- 5. Kupke T. 2002. Molecular characterization of the 4'-phosphopantothenoylcysteine synthetase domain of bacterial dfp flavoproteins.. J Biol Chem 277(39):36137-45 PMID: 12140293
- 6. Stanitzek S et al.. 2004. Structural basis of CTP-dependent peptide bond formation in coenzyme A biosynthesis catalyzed by Escherichia coli PPC synthetase.. Structure 12(11):1977-88 PMID: 15530362
- 7. Strauss E et al.. 2001. Mechanistic studies on phosphopantothenoylcysteine decarboxylase.. J Am Chem Soc 123(26):6449-50 PMID: 11427085
- 8. Patrone JD et al.. 2009. Selective inhibitors of bacterial phosphopantothenoylcysteine synthetase.. J Am Chem Soc 131(45):16340-1 PMID: 19902973
